Technetium (99mTc) sulesomab
| Monoclonal antibody | |
|---|---|
| Type | Fab' fragment |
| Source | Mouse |
| Target | NCA-90 (granulocyte cell antigen) |
| Clinical data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Technetium (99mTc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mouse monoclonal antibody[1] that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99m radionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of 99mTc-antibody bound cells.[2] Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation[3]
It is approved in European markets for the imaging of infections and inflammations in patients with suspected osteomyelitis[4][5] but has not secured FDA approval for use in American markets.[6] In addition to approved uses, Leukoscan is currently being investigated for other diagnostic purposes like the detection of soft tissue infections, malignant external otitis and prosthetic joint infection.[7][8][9] However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent company Immunomedics was discontinued in 2018.[10]
References
[edit]- ^ "WHO Drug Information" (PDF). Archived from the original (PDF) on 2012-02-19. Retrieved 2009-10-25.
- ^ Quigley AM, Gnanasegaran G, Buscombe JR, Hilson AJ (2008). "Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections". Medical Principles and Practice. 17 (6): 447–52. doi:10.1159/000151565. PMID 18836272.
- ^ Skehan SJ, White JF, Evans JW, Parry-Jones DR, Solanki CK, Ballinger JR, et al. (January 2003). "Mechanism of accumulation of 99mTc-sulesomab in inflammation". Journal of Nuclear Medicine. 44 (1): 11–8. PMID 12515870. Archived from the original on 2019-12-10. Retrieved 2019-12-10.
- ^ EMEA: Summary of product characteristics (LeukoScan) Archived 2006-11-22 at the Wayback Machine
- ^ Gratz S, Reize P, Kemke B, Kampen WU, Luster M, Höffken H (December 2016). "Targeting osteomyelitis with complete [99mTc]besilesomab and fragmented [99mTc]sulesomab antibodies: kinetic evaluations". The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 60 (4): 413–23. PMID 25325395.
- ^ Vicente AG, Almoguera M, Alonso JC, Heffernan AJ, Gomez A, Contreras PI, Martin-Comin J (December 2004). "Diagnosis of orthopedic infection in clinical practice using Tc-99m sulesomab (antigranulocyte monoclonal antibody fragment Fab'2)". Clinical Nuclear Medicine. 29 (12): 781–5. doi:10.1097/00003072-200412000-00001. PMID 15545877. S2CID 46580717.
- ^ Quigley AM, Gnanasegaran G, Buscombe JR, Hilson AJ (2008). "Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections". Medical Principles and Practice. 17 (6): 447–52. doi:10.1159/000151565. PMID 18836272.
- ^ Galletti F, Cammaroto G, Galletti B, Quartuccio N, Di Mauro F, Baldari S (June 2015). "Technetium-99m (99mTc)-labelled sulesomab in the management of malignant external otitis: is there any role?". European Archives of Oto-Rhino-Laryngology. 272 (6): 1377–82. doi:10.1007/s00405-014-2938-1. PMID 24534898. S2CID 25194736.
- ^ Iyengar KP, Vinjamuri S (June 2005). "Role of 99mTc Sulesomab in the diagnosis of prosthetic joint infections". Nuclear Medicine Communications. 26 (6): 489–96. doi:10.1097/00006231-200506000-00003. PMID 15891591. S2CID 41915486.
- ^ "Products". Immunomedics. Archived from the original on 2019-12-10. Retrieved 2019-12-10.
See also
[edit]
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |